DICE Therapeutics, Inc.
DelistedCIK 1645569fmd_06TQVGR87FCHHFPAXRDXVVMQANManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Jun 30, 2023, 14 periods
Latest annual · FY2021
Millions- Total revenues
- 1
- Operating income
- (88)
- Net income
- (84)
- Free cash flow
- (67)
Latest quarter · Q2 FY2023
Millions- Operating income
- (39)
- Net income
- (35)
- Free cash flow
- (30)
DICE Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Operating income | -$88.2 million | -$47.6 million | 10-K 2023-03-15 · proof | |
| Net income | -$83.9 million | -$49 million | 10-K 2023-03-15 · proof | |
| Cash from operating activities | -$64.3 million | -$39.3 million | 10-K 2023-03-15 · proof | |
| Free cash flow | -$66.6 million | -$40 million | 10-K 2023-03-15 · proof | |
| Total assets | $594 million | $325.8 million | +82.3% | 10-K 2023-03-15 · proof |
| Total liabilities | $27 million | $12.8 million | +110.8% | 10-K 2023-03-15 · proof |
| Cash and cash equivalents | $461.4 million | $115.8 million | +298.4% | 10-K 2023-03-15 · proof |
- What was DICE Therapeutics, Inc.'s operating income in fiscal 2022?
- DICE Therapeutics, Inc. reported operating income of -$88.2 million for fiscal 2022 (the year ended Dec 31, 2022), against -$47.6 million the year before. Source: the 10-K filed with the SEC on Mar 15, 2023. SEC
- What was DICE Therapeutics, Inc.'s net income in fiscal 2022?
- DICE Therapeutics, Inc. reported net income of -$83.9 million for fiscal 2022 (the year ended Dec 31, 2022), against -$49 million the year before. Source: the 10-K filed with the SEC on Mar 15, 2023. SEC
- What was DICE Therapeutics, Inc.'s cash from operating activities in fiscal 2022?
- DICE Therapeutics, Inc. reported cash from operating activities of -$64.3 million for fiscal 2022 (the year ended Dec 31, 2022), against -$39.3 million the year before. Source: the 10-K filed with the SEC on Mar 15, 2023. SEC
- What was DICE Therapeutics, Inc.'s free cash flow in fiscal 2022?
- DICE Therapeutics, Inc. reported free cash flow of -$66.6 million for fiscal 2022 (the year ended Dec 31, 2022), against -$40 million the year before. Source: the 10-K filed with the SEC on Mar 15, 2023. SEC
- What are DICE Therapeutics, Inc.'s total assets?
- As of Dec 31, 2022, DICE Therapeutics, Inc. reported total assets of $594 million, against $325.8 million a year earlier (+82.3%). Source: the 10-K filed with the SEC on Mar 15, 2023. SEC
- What are DICE Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2022, DICE Therapeutics, Inc. reported total liabilities of $27 million, against $12.8 million a year earlier (+110.8%). Source: the 10-K filed with the SEC on Mar 15, 2023. SEC
- What are DICE Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2022, DICE Therapeutics, Inc. reported cash and cash equivalents of $461.4 million, against $115.8 million a year earlier (+298.4%). Source: the 10-K filed with the SEC on Mar 15, 2023. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1645569&period_type=annual&limit=5"Information only, not investment advice.